AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials

Summary

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.”

Description

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting pipeline of new medicines.”

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage